Maduck Sean has filed a report detailing several stock transactions involving Corcept Therapeutics Inc., a company in the pharmaceutical preparations sector. This filing, dated October 5, 2026, is significant as it provides insights into the stock activities of a key officer within the company.
Company Overview
Corcept Therapeutics Inc. is a Delaware-based company focused on developing and commercializing innovative treatments for patients with severe metabolic and psychiatric disorders. The company is listed under the standard industrial classification of pharmaceutical preparations.
Details of the Filing
According to the filing (accession number 0001193125-26-414674), Sean Maduck engaged in multiple transactions involving Corcept's common stock. Notably, on October 1, 2026, he acquired 413 shares at a price of $8.27 each. Additionally, he disposed of 413 shares at a significantly higher price of $115.5373 per share on the same day.
The following day, October 2, 2026, Maduck acquired another 24,587 shares at $8.27 each and disposed of 15,843 shares at an average price of $116.1233. These transactions reflect a strategic approach to managing his stock holdings in the company, with a total of 34,525 shares owned following these transactions.
Impact of the Transactions
These transactions may affect investor sentiment regarding Corcept Therapeutics, as they highlight the active involvement of its leadership in stock management. Such activities can signal confidence in the company's future prospects or reflect personal financial strategies. The pharmaceutical industry often scrutinizes insider transactions, which can influence market perceptions and stock performance.
What's Next?
The filing does not say what happens next regarding these transactions or any potential future filings. However, continued monitoring of insider activities may provide further insights into Corcept's strategic direction.